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Outcome in Patients with MDS
Aaron T. Gerds,1,2 Ted A. Gooley,1,2 Elihu H. Estey,1,2
Frederick R. Appelbaum,1,2 H. Joachim Deeg,1,2 Bart L. Scott1,2Although allogeneic hematopoietic cell transplantation (HCT) has proven curative potential for myelodys-
plastic syndrome, relapse after HCT remains a problem. Pretransplantation cytoreduction with induction
chemotherapy (IC) has been used to reduce relapse rates but is associated with significant toxicity and
mortality. Hypomethylating agents may achieve cytoreduction with limited toxicity; however, data on the
effect of pre-HCT hypomethylation on post-HCToutcomes are limited.We retrospectively reviewed results
in 68 patients who underwent allogeneic HCT for myelodysplastic syndrome or acute myeloid leukemia
transformed from MDS. Thirty-five patients had received cytoreduction with azacitidine before HCTwith
either a high-dose (40%) or a reduced-intensity (60%) conditioning regimen, and 33 had undergone IC before
HCT with high-dose conditioning. The estimated 1-year overall survival (OS) was 57% in the azacitidine
group and 36% in the IC group. The risk of post-HCT mortality (hazard ratio, 0.68; 95% confidence interval,
0.35-1.30), nonrelapse mortality (hazard ratio, 0.99; 95% confidence interval, 0.41-2.34), and relapse (hazard
ratio, 0.34; 95% confidence interval, 0.41-2.34) were lower in the azacitidine group compared to the IC
group, but only the hazard for relapse was significantly lower. After adjustment for cytogenetic risk, Interna-
tional Prognostic Scoring System, and donor, the rates of post-HCTrelapse for the 2 cohorts were similar.
Although the current study was retrospective and nonrandomized and needs to be interpreted in this con-
text, the results add to the growing evidence that pre-HCT therapy with azacitidine is associated with less
toxicity than IC and may allow for similar post-HCToutcomes.
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Reduced-intensity conditioningINTRODUCTION
Myelodysplastic syndrome (MDS) represents
a group of clonal myeloid stem cell disorders with
a heterogeneous spectrum of presentation ranging
from an indolent course over several years to rapid
progression to acute myeloid leukemia (AML). The
natural history of patients with MDS is varied with
a median survival ranging from 5.7 years for patients1Fred Hutchinson Cancer Research Center, Seattle,
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(IPSS), to 0.4 years for those with high-risk scores at
the time of diagnosis. The only known curative treat-
ment modality for MDS is allogeneic hematopoietic
cell transplantation (HCT). Yet, despite the demon-
strated benefit of HCT, patients with advanced MDS
are at a substantial risk of relapse after HCT [1-3]. A
central question, therefore, is whether patients
should receive pre-HCT ‘‘debulking’’ therapy to re-
duce the risk of post-HCT relapse, and if so, what is
the optimum modality to achieve that objective? As
MDS is primarily a disease of older age, often compli-
cated by medical comorbidities, a major concern is
toxicity and mortality related to intensive treatment.
Several retrospective studies have explored the efficacy
of induction chemotherapy (IC) before HCT aimed at
decreasing the rate of relapse and improving post-
transplantation outcomes [4-6]. Pretransplantation
IC may reduce the incidence of post-HCT relapse
but is associated with considerable morbidity andmor-
tality, and patients may not come to HCT. In fact,1211
1212 Biol Blood Marrow Transplant 18:1211-1218, 2012A. T. Gerds et al.a prospective study of 259 patients with high-risk
MDS or AML over the age of 50 years found that of
the 99 patients who achieved complete remissions after
IC, only 53 had a consultation considering HCT, and
just 14 patients ultimately received an HCT [7]. The
remaining patients were not considered well enough
for HCT for various reasons, including their clinical
status before IC.
Administration of the azanucleosides, azacitidine
and decitabine, is associated with only mild toxicity
and has been shown to delay progression to AML
and, in the case of azacitidine, to extend survival by
9.5 months as compared to conventional care [8-10].
Given their activity against MDS and the low
toxicity profile, azanucleosides represent an attractive
alternative to traditional IC as a pre-HCT cytoreduc-
tive modality.
The ideal strategy to discern the post-HCT bene-
fit of pre-HCT cytoreductive therapy, and to identify
the optimal agent, would be in the form of a random-
ized prospective study. Patients enrolled would be ran-
domized to 1 of 3 arms; either proceed to immediate
HCT, or receive pre-HCT cytoreduction with IC,
or with azacitidine. Such a study has not been con-
ducted andmay not be feasible or practical. In fact, sev-
eral studies designed and launched to answer similar
questions have been closed due to poor accrual. With
the lack of randomized prospective data, and despite
the inherent limitations, retrospective analyses provide
the only means to generate evidence on which to base
clinical practice. Thus, to compare the usefulness of
pre-HCT azacitidine and IC for post-HCT outcome,
we conducted a retrospective analysis of post-HCT re-
sults in patients with advanced MDS who underwent
pre-HCT cytoreduction at our institution.PATIENTS AND METHODS
Patients
Consecutive patients with advancedMDS or AML
developing from antecedent MDS (transformed acute
myelogenous leukemia [tAML]) who received an allo-
geneic HCT between August 2004 andMay 2010 were
screened for treatment with azacitidine before HCT.
Included were patients who received other chemother-
apeutic interventions before azacitidine. However,
patients who received other chemotherapy after azaci-
tidine and before HCT were excluded. A historical
cohort comprising patients with advanced MDS or
tAML, who received IC before HCT at our center
from December 1992 to October 2002, was included
in the analysis as a comparator group [5].
Patients who received azacitidine were older than
IC-treated patients (median, 60 vs 47 years). The ma-
jority of patients in both groups had de novo disease.
The median time from diagnosis to HCT was similarfor the 2 groups. Patients for whom bone marrow
biopsies were available to evaluate cellularity before
cytoreductive therapy, all showed hypercellular mar-
rows with a cellularity .60%. There were more pa-
tients with advanced MDS/tAML in the IC-treated
group. However, there were no significant differences
between the groups regarding marrow myeloblast
count at the time of HCT (Table 1).
Pretransplantation Therapy
The initiation and duration of treatment with
azacitidine or IC was at the discretion of the treating
physician. Azacitidine was administered at doses of
75 mg/m2/day on days 1 through 7 of a 28-day cycle
[8]. A minimum of 1 cycle of azacitidine was adminis-
tered before proceeding to HCT. The median cycles
of azacitidine administered was 3 (range, 1-11). Among
the patients who received IC, most (61%) were given
cytarabine for 7 days and an anthracycline for 3 days
(713). Other patients received topotecan and cytara-
bine (21%), dexamethasone, cytarabine, thioguanine,
etoposide, daunorubicin (12%), fludarabine, cytara-
bine, filgrastim (3%), and high-dose cytarabine (3%).
Patients received IC 1 to 6 months (median, 2 months)
before HCT.
Transplantation Conditioning Regimens
All patients in the IC group were conditioned with
high-dose regimens, whereas in the azacitidine group,
14 patients (40%) underwent conditioning with high-
dose regimens, and 21 (60%) received reduced-
intensity conditioning (RIC), as previously defined
(P\ .001) [11]. Overall, 33 patients were conditioned
with a previously described regimen comprising tar-
geted busulfan (tBu) and cyclophosphamide (Cy;
tBuCy) [12].
Twelve patients, all in the IC group, were condi-
tioned with Bu and total body irradiation (TBI;
BuTBI) [13]. TBI and Cy were used for 1 patient in
the azacitidine group [14]. Fludarabine (Flu) and tar-
geted Bu (FluBu) was used to condition 1 patient in
the azacitidine group [15]. Eleven patients in the azaci-
tidine group were conditioned with Flu and low-dose
TBI (FluTBI) [16], while 6 received treosulfan
(Treo), Flu, and low-dose TBI (TreoFluTBI; 3  14
g/m2 of Treo, 5  30 mg/m2 of intravenous [IV] Flu,
and 200 cGy TBI).
Two patients were conditioned with radiolabeled
anti-CD45 antibody plus Flu and low-dose TBI
(FluTBI 1 I-131) [17]. One patient in the azacitidine
group received radiolabeled anti-CD45 antibody
with Flu, low-dose TBI, and cyclophosphamide before
and after stem cell infusion (FluCyTBI 1 I-131; 0.5
mg/kg of 131I-anti-CD45 antibody, 2  14.5 mg/kg
of Cy, 5  30 mg/m2 of IV Flu, 200 cGy TBI, and
50 mg/kg Cy post-HCT), and 1 patient was
Table 1. Patient and Disease Characteristics
Characteristic
Pretransplantation Therapy
AZA IC
No. of patients 35 33
Age, y, range (median) 4-74 (60) 2-64 (47)
Gender, M/F, no. of patients 22/13 17/16
Etiology, no. of patients (%)
De novo 29 (83) 28 (85)
Secondary 6 (17) 5 (15)
Disease duration in months (range, median) 4-112 (9) 0-62 (7)
WHO Classification, no. of patients (%)
RARS 2 (6) 2 (6)
RCMD 9 (26) 3 (9)
RAEB-1 3 (9) 7 (21)
RAEB-2 12 (34) 10 (30)
tAML 2 (6) 11 (33)
CMML 3 (9) 0 (0)
JMML 1 (3) 0 (0)
MDS-U 3 (9) 0 (0)
IPSS risk group, no. of patients (%)
Low 6 (17) 0 (0)
Intermediate-1 11 (31) 10 (30)
Intermediate-2 9 (26) 8 (24)
High 9 (26) 15 (45)
Cytomegalovirus serology, no. of
patients (%)
Positive 27 (77) 20 (61)
Negative 8 (23) 13 (39)
Myeloblast at transplantation, no. of
patients (%)
<5% 18 (51) 19 (58)
5%-9% 8 (23) 5 (15)
10%-19% 7 (20) 5 (15)
$20% 2 (6) 4 (12)
GVHD prophylaxis, no. of patients (%)
MTX, cyclosporine 1 (3) 27 (82)
MTX, tacrolimus 15 (43) 0 (0)
MTX, cyclosporine, tacrolimus 0 (0) 1 (3)
MTX, tacrolimus, rapamycin 1 (3) 0 (0)
Cy, MMF 15 (43) 4 (12)
Tacrolimus and MMF 2 (6) 0 (0)
Tacrolimus, MMF, Cy 1 (3) 0 (0)
T cell depletion 0 (0) 1 (3)
Donor, no. of patients (%)
HLA-identical sibling 13 (37) 16 (48)
HLA-identical unrelated 13 (37) 17 (52)
Alternative related donor 1 (3) 0 (0)
HLA-mismatched unrelated 5 (14) 0 (0)
Umbilical cord blood 3 (9) 0 (0)
Conditioning regimen, no. of patients (%)
tBuCy 12 (34) 21 (64)
BuTBI 0 (0) 12 (36)
CyTBI 1 (3) 0 (0)
FluBu 1 (3) 0 (0)
FluTBI (200) 11 (31) 0 (0)
TreoFluTBI (200) 6 (17) 0 (0)
FluTBI (200) + I-131 2 (6) 0 (0)
FluCyTBI (200) + I-131 1 (3) 0 (0)
FluCyTBI (200) + ATG 1 (3) 0 (0)
Conditioning intensity, no. of patients (%)
High intensity 14 (40) 33 (100)
Reduced intensity 21 (60) 0 (0)
AZA indicates azacitidine; IC, induction chemotherapy; WHO, World
Health Organization; RARS, refractory anemia with ringed sideroblasts;
RCMD, refractory cytopenias with multilineage dysplasia; RAEB, refrac-
tory anemia with excess blasts; t-AML, acute myeloid leukemia
transformed from myelodysplastic syndrome; CMML, chronic myelo-
monocytic leukemia; JMML, juvenile myelomonocytic leukemia; MDS-U,
myelodysplastic syndrome–unclassified; IPSS, International Prognostic
Scoring System; GVHD, graft-versus-host disease; MTX, methotrexate;
MMF, mycophenolate mofetil; Cy, cyclophosphamide; tBuCy, targeted
Biol Blood Marrow Transplant 18:1211-1218, 2012 1213Azacitidine vs IC before Allogeneic Transplantconditioned with a regimen comprising Flu, Cy, low-
dose TBI, and anti-thymocyte globulin (ATG; Flu-
CyTBI 1 ATG; 50 mg/kg Cy, 3  30 mg/kg of
ATG, 5  40 mg/m2 Flu, and 200 cGy TBI).
Donors and Source of Hematopoietic Cells
Twenty-nine patients received hematopoietic cells
from HLA-matched siblings and 30 from HLA-
matched unrelated donors. Patients in the azacitidine
group were more likely to have received stem cells
from alternative donors (P 5 .002). Five patients re-
ceived stem cells from HLA-mismatched unrelated
donors, 3 patients received umbilical cord blood
(2 units), and 1 patient received stem cells from an
HLA-haploidentical related donor.
Graft-versus-Host Disease Prophylaxis and
Treatment
Graft-versus-host disease (GVHD) prophylaxis
consisted of i.v. methotrexate and cyclosporine in 28
patients [18], methotrexate and tacrolimus in 15 pa-
tients [19], cyclosporine and mycophenolate mofetil
in 19 patients [20], andmiscellaneous regimens in 6 pa-
tients (Table 1). First-line treatment of acute GVHD
consisted of methylprednisolone at doses of 1 or 2
mg/kg/day depending on the severity of presentation.
The treatment of steroid-refractory GVHD included
a variety of approaches [21].
Supportive Care
Antimicrobial prophylaxis consisted of acyclovir,
a fluoroquinolone, and either fluconazole or voricona-
zole. Granulocyte colony-stimulating factor was not
routinely used after HCT as part of supportive care.
Trimethoprim/sulfamethoxasole or dapsone was given
for prophylaxis of Pneumocystis jiroveci. All patients un-
derwent surveillance for cytomegalovirus reactivation
and were treated with preemptive ganciclovir, valgan-
ciclovir, or foscarnet, as appropriate.
Definition of Endpoints
The primary endpoint in this analysis was overall
survival (OS). Secondary endpoints were relapse,
nonrelapse mortality (NRM), relapse-free survival
(RFS), and GVHD. Relapse was defined as the pres-
ence of myeloid cells with immunophenotypic abnor-
malities identified by flow cytometry consistent with
those beforeHCT,morphologic evidence of dysplasia,
or the presence of cytogenetic abnormalities identifiedbusulfan and cyclophosphamide; BuTBI, busulfan total body irradiation;
CyTBI, cyclophosphamide total body irradiation; FluBu, fludarabine and
targeted busulfan; FluTBI, fludarabine total body irradiation; TreoFluTBI,
treosulfan fludarabine total body irradiation; FluCyTBI, Fludarabine
cyclophosphamide total body irradiation; I-131, radiolabeled anti-
CD45 antibody; ATG, antithymocyte globulin.
Figure 1. Overall survival after hematopoietic cell transplantation
(HCT) according to pretransplantation therapy: azacitidine (AZA) vs in-
duction chemotherapy (IC). Patients were censored at the last follow-
up. The difference between AZA and IC was not significant at P 5 .24.
Table 2. Regression Analysis of HCTOutcomes
Univariate Analysis
Excluding AML
Patients
Outcome HR (95% CI) P value HR (95% CI) P value
Overall survival 0.68 (0.35-1.30) .24 0.73 (0.35-1.51) .39
Relapse 0.34 (0.12-0.94) .04 0.35 (0.12-1.01) .05
Nonrelapse mortality 0.99 (0.41-2.34) .98 1.2 (0.43-3.31) .73
Relapse-free survival 0.62 (0.33-1.16) .14 0.66 (0.33-1.32) .23
Adjusted for Cyto Risk, IPSS, and Donor
Outcome HR (95% CI) P value HR (95% CI) P value
Overall survival 0.87 (0.44-1.69) .68 0.9 (0.43-1.9) .79
Relapse 043 (0.15-1.20) .10 0.41 (0.14-1.2) .11
Nonrelapse mortality 1.06 (0.45-2.54) .88 1.37 (0.49-3.82) .55
Relapse-free survival 0.72 (0.38-1.38) .32 0.78 (0.38-1.57) .48
HCT indicates hematopoietic cell transplantation; HR, hazard ratio; CI,
confidence interval; AML, acute myeloid leukemia; cyto, cytoreduction;
IPSS, International Prognostic Scoring System.
Hazard ratio (HR) reflects hazard of failure in group that received azaci-
tidine relative to the hazard of failure in the group that received induc-
tion chemotherapy.
1214 Biol Blood Marrow Transplant 18:1211-1218, 2012A. T. Gerds et al.before HCT. GVHD was diagnosed and graded ac-
cording to consensus criteria [22]. Relapse was consid-
ered the primary cause of failure in patients with
evidence of relapse regardless of the proximate cause
of death [23].
Statistical Analysis
Data were analyzed as of March 24, 2011. OS and
RFS were estimated using the Kaplan-Meier method
[24]. Relapse andNRMwere summarized using cumu-
lative incidence estimates, with NRM a competing risk
for relapse, and relapse a competing risk for NRM.
Cox regression was used to compare the hazards of
failure between the azacitidine and IC groups for the
endpoints OS, NRM, RFS, and relapse, and logistic
regression was used for acute GVHD.RESULTS
Overall Survival and Nonrelapse Mortality
Themedian post-HCT follow-up among survivors
was 10.6 months (range, 2.6-59.5 months) for the
azacitidine group and 95.9 months (range, 78.6-180.3
months) for the IC group. At the time of analysis,
20 and 9 patients were alive in the azacitidine and the
IC groups, respectively. There were no engraftment
failures in either group. The 100-day mortality for
the azacitidine group was 29% vs 27% in the IC group
(Figure 1). The estimated 1-year OS was 57% in the
azacitidine group and 36% in the IC group. The risk
of post-HCT mortality was 32% lower in the azaciti-
dine group compared with the IC group (hazard ratio
[HR], 0.68; 95% confidence interval [CI], 0.35-1.30);
after adjusting for cytogenetic risk, IPSS, and type of
donor, the reduction in mortality hazard was lessened
to 13%—neither of these reductions was statistically
significant. We performed the same analysis excludingpatients in whom MDS had progressed to AML, and
the findings were similar (unadjusted HR, 0.72;
adjusted HR, 0.9; Table 2).
Seven patients in the azacitidine cohort died while
in remission. Causes of death included infection and
multisystem organ failure (4 patients) with or without
GVHD (2 patients). One patient committed suicide.
In the IC cohort, 9 patients died without evidence of
MDS or AML. Five of these patients died with
GVHD associated with infection or organ failure,
and 4 patients died as a result of infections. Eight pa-
tients (23%) in the azacitidine group and 15 patients
(45%) in the IC group died from relapse. Post-HCT
NRM was similar for the azacitidine group relative
to the IC group both before and after adjustment for
cytogenetic risk, IPSS, and type of donor (Figure 2).
An analysis excluding patients with transformation to
AML showed that the azacitidine cohort had a slightly
higher hazard for NRM, which, however, was not
statistically significant (Table 2).
Relapse and Relapse-Free Survival
Ten patients (29%) in the azacitidine group and 13
patients (39%) in the IC group had evidence for recur-
rent disease after HCT; 2 patients in the azacitidine
group were alive with post-HCT relapse at the time
of analysis. One patient in each group relapsed within
30 days of HCT, and 2 patients in each group relapsed
more than 1 year after HCT (Figure 3). Pre-HCT ex-
posure to azacitidine led to a 66% lower hazard of re-
lapse compared to IC, which was significantly different
(CI, 0.12-0.94; P 5 .04). After adjustment for cytoge-
netic risk, IPSS, and donor type, the hazard of relapse
was still 58% lower with azacitidine, but after adjust-
ment, the findings were no longer statistically
Figure 2. Nonrelapse mortality following hematopoietic cell trans-
plantation (HCT) according to pretransplantation therapy: azacitidine
(AZA) vs induction chemotherapy (IC). Patients were censored at the
last follow-up. The difference between AZA and IC was not significant
at P 5 .98.
Figure 4. Relapse-free survival (RFS) after HCTaccording to pretrans-
plantation therapy: azacitidine (AZA) vs induction chemotherapy (IC).
Patients were censored at the last follow-up. The difference between
AZA and IC was not significant at P 5 .14.
Biol Blood Marrow Transplant 18:1211-1218, 2012 1215Azacitidine vs IC before Allogeneic Transplantsignificant (P 5 .10). The hazard for relapse remained
lower after the exclusion of patients with AML, but
these differences were no longer statistically significant
(unadjusted P 5 .05, adjusted for cytogenetic risk,
IPSS, and donor type P 5 .11). The risk of relapse or
death was reduced by 38% in the azacitidine group be-
fore adjustment and by 27% after adjustment; neither
difference was statistically significant (Figure 4 and
Table 2).
GVHD
Twenty-four of 34 evaluable patients (71%) in the
azacitidine group, and 24 of 31 patients (77%) in the
IC group developed grades II to IV acute GVHD.
The odds of grades II to IV acute GVHD were re-
duced by 33% in the azacitidine group before adjust-
ment and by 40% after adjustment, but neither
difference was statistically significant. Only 2 patientsFigure 3. Relapse after hematopoietic cell transplantation (HCT) ac-
cording to pretransplantation therapy: azacitidine (AZA) vs induction
chemotherapy (IC). Patients were censored at the last follow-up. The
difference between AZA and IC was significant at P 5 .04.(6%) in the azacitidine group developed grades III to
IV acute GVHD as compared to 13 patients (42%)
in the IC group. The difference was statistically signif-
icant (OR, 0.10; 95%CI, 0.02-0.48; P5 .004) after ad-
justment (Table 3). Chronic GVHD occurred in 11
patients (32%) in the azacitidine group and in 13 pa-
tients (42%) who received IC.DISCUSSION
Although advances have been made in recent years
in the nontransplantation treatment of MDS, alloge-
neic HCT remains the only modality with known cu-
rative potential [25]. MDS is currently the third most
common indication for allogeneic HCT as reported
to the Center for International Blood and Marrow
Transplantation Research [26]. Due to the high fre-
quency of advanced disease state at HCT, post-
transplantation relapse remains a major cause of
failure of HCT for MDS [1-3]. PretransplantationTable 3. Graft-versus-Host Disease
Univariate Analysis
Outcome OR (95% CI) P value
Grades 2–4 aGVHD 0.67 (0.21-2.16) .50
Grades 3–4 aGVHD 0.10 (0.02-0.48) .0044
Adjusted for Donor
Outcome OR (95% CI) P value
Grade 2–4 aGVHD 0.60 (0.17-2.08) .42
Grade 3–4 aGVHD 0.09 (0.02-0.45) .05
OR indicates odds ratio; CI, confidence interval; aGVHD, acute graft-
versus-host disease.
Odds ratio (OR) reflects hazard of failure in the group that received aza-
citidine relative to the hazard of failure in the group that received induc-
tion chemotherapy.
1216 Biol Blood Marrow Transplant 18:1211-1218, 2012A. T. Gerds et al.chemotherapy, similar to that used as IC for AML, has
been used in this setting [4-6]. More recently, a form of
low-intensity therapy with hypomethylating azanu-
cleosides has been shown in randomized phase III tri-
als in the nontransplantation setting to decrease the
risk of or delay leukemic transformation and prolong
survival by approximately 9 months [8-10]. These
agents offer attractive therapy options for MDS, as
the largest barriers to effective treatment are patient
age and comorbidities and the associated decreased
ability to tolerate high-dose therapy.
Azanucleosides are now commonly administered
as pre-HCT cytoreductive therapy for patients with
MDS. However, data are lacking in regard to their ef-
fect on HCT outcomes, particularly in comparison to
traditional IC. The American Society for Blood and
Marrow Transplantation has, therefore, identified
pre-HCT cytoreductive therapy as a critical area for
further investigation [27].
The current study presents results in 2 cohorts
of patients with high-risk MDS: 1 cohort treated
pre-HSCT with conventional IC, the other with azaci-
tidine. The cohorts were nonconcurrent and non-
randomized, and therefore, results must be interpreted
with caution. As advances have been made in the treat-
ment of AML, the OS has improved [28], and it is pos-
sible that a concurrent comparative group would yield
different results. However, few patients concurrently
treated with ICwere available, underscoring the prefer-
ence of clinicians for hypomethylation, even though
randomized trials are lacking. Additionally, there is an
imbalance in diagnosis, with more patients with trans-
formation to AML treated with IC as opposed to
MDS. Nevertheless, the results are consistent with re-
ports by others and show that pre-HCT therapy with
azacitidine was well tolerated and resulted in post-
HCToutcomes that did not show any evidence of being
worse than those observed with IC, even after adjusting
for various risk factors. The present results also indicate
that despite the significantly older age of patients in the
azacitidine cohort, NRMwas not higher than observed
in younger patients of the IC cohort. Of course, compa-
rability is limited, as younger patients typically received
IC pre-HCT and were conditioned with high-intensity
transplantation conditioning regimens. The ideal
method to address these issues would be a prospective
randomized trial; however, prior attempts to conduct
randomized trials evaluating pretransplantation treat-
ment inMDShave failed due to lack of accrual.We cal-
culated that if the true reduction in mortality was 32%
with azacitidine as suggested in our data, then 220 pa-
tients would need to be randomized between IC and
azacitidine in order tohave 80%power todetect this de-
gree of difference.
There was a trend toward lower rates of acute
GVHD in patients pretreated with azacitidine, which
was significant for grades III to IV disease. This out-come may be related to lessened tissue injury by
azacitidine (compared to IC) [14,29,30], or a direct
anti-GVHD effect of azacitidine, as also suggested
by others [31,32].
Several transplantation teams have reported data
on the pre-HCT use of hypomethylating agents. Field
et al. [33] analyzed results in a cohort of 54 consecutive
patients with MDS who underwent allogeneic HCT,
divided into 2 groups based on treatment with azaciti-
dine beforeHCT.Thirty patients received azacitidine,
and 24 did not. Six of the 30 patients in the azacitidine
group and 10 of the 24 in the comparator group pro-
gressed to AML and were treated with IC before
HCT. All patients were conditioned for HCT with
a high-dose regimen of Flu and Bu. The cumulative
incidence of NRM was similar for the 2 groups. The
1-year estimates of OS, RFS, and cumulative incidence
of relapse were 47%, 41%, and 20% for patients who
had received azacitidine, vs 60%, 51%, and 32% for
those who had not. While azacitidine treatment did
not seem to result in a net gain, the authors suggested
that azacitidine could be a useful bridge to HCT.
Recently, Kim et al. [34] reported the outcomes in
19 patients whowere treated with azacitidine or decita-
bine. Three patients developed progressive disease be-
fore HCT and were given IC with anthracycline and
cytarabine. Eighteen of the patients underwent HCT
after RIC. NRM was 11%. The OS rates at 1 and 2
years were 95% and 68%, respectively. At the most re-
cent follow-up, 13 patients were alive, and 4 had died
due to relapse and progression to AML. The reported
1-year OS in this study was higher than in the
azacitidine-treated patients in the present study. How-
ever, the studies are not strictly comparable, as patient
and disease-risk parameters differed considerably.
Similar results have been reported in smaller
patient cohorts by other investigators [35-37].
Although azacitidine and decitabine may differ in
their mechanism of action, results with both agents
were comparable. The results of these previously
reported studies are comparable to the outcomes of
the azacitidine cohort in the present study. The small
number of patients included in the single-arm studies
limited the power of analysis. Also, 27% of the patients
in 1 study (L€ubbert et al. [37]), as well as 25% (Cogle
et al. [35]), and30% (Field et al. [33]) in others, received
second-line cytoreduction with either low-dose mel-
phalan or IC (similarly treated patients were excluded
from the present study), confounding the effect of
hypomethylating agents on post-HCT outcomes.
McCarty et al. [38] investigated the role of azaciti-
dine vs IC in the pre-HCT setting in 25 patients with
high-risk MDS or tAML. Patients received 4 cycles of
azacitidine, then, based on myeloblast count, they ei-
ther received more azacitidine or, if there was no evi-
dence of response, crossed over to IC with
fludarabine, cytarabine, filgrastim. Twenty-one of
Biol Blood Marrow Transplant 18:1211-1218, 2012 1217Azacitidine vs IC before Allogeneic Transplantthe patients went on to receive HCT after a high-dose
conditioning regimen. With 1-year follow-up, both
NRM and relapse rates were higher among patients
who received IC, not a surprising outcome, as the
study was designed such that only patients who did
not respond to azacitidine received IC before trans-
plantation.
The retrospective nature of the current study and
the sequential treatment intervals of the 2 cohorts limit
the conclusions that can be drawn, as recent reports
note improved HCT outcomes and AML treatment
results have improved over time [28,39]. However,
we chose a comparator group that predated the
widespread use of azacitidine as cytoreductive or
bridging therapy before HCT, thereby reducing the
potentially confounding effect of a bias in treatment
selection. Treatment selection bias may exert an
influence on post-HCT outcomes as more practi-
tioners and patients may opt for therapy with low tox-
icity as a pre-HCT regimen. It is not unlikely that
patients, who previously would have received IC,
now are treated with a hypomethylating agent instead.
An important concept materializing concurrently
with the advent of hypomethylating agents is the devel-
opment of RIC regimens and the relationship between
the selection of pre-HCT therapy and the subsequent
HCT conditioning regimen. It is reasonable to view
the selection of a pre-HCT cytoreductive or bridging
regimen and the proposed conditioning approach as
a ‘‘package.’’ In addition to relapse, the major cause of
failure in patients who underwent transplantation for
MDS is NRM. The most powerful predictors of
NRM are patient comorbidities and conditioning-
regimen intensity. Patient and disease characteristics
are a given; however, the regimen can be selected, and
that selection should probably take into consideration
the pre-HCT therapy the patient received [40,41].
In addition to cytoreduction as achieved with
conventional IC, hypomethylating agents may offer
benefits in regard to relapse reduction via epigenetic
modulation. Several studies have described the methyl-
ation of promoter regions involved with the tumor
suppressor genes CDH1 (E-cadherin) and CTNNA1
(catenin), as well as genes regulating the cell cycle such
as CDKN2A (p16INK4a) and CDKN2B (p15INK4b) in
patients with MDS [42,43]. Furthermore, enhanced
expression of cancer-testis antigens after hypomethyla-
tion may allow for a greater graft-vs-leukemia effect
mediated by donor cells after HCT [44].
In summary, the results of our analysis support the
concept that hypomethylating drugs are suitable for
pre-HCT therapy and may offer advantages over con-
ventional IC. However, many questions remain in re-
gard to disease stage most amenable to this therapy,
timing, number of cycles, and possibly the optimum
transplantation conditioning regimens to be used in
combination with azacitidine pre-HCT.ACKNOWLEDGMENTS
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